Dow Up2.00% Nasdaq Up1.66%

Allergan plc (AGN)

-NYSE
280.48 Up 5.93(2.16%) Feb 12, 4:02PM EST
|After Hours : 278.00 Down 2.48 (0.88%) Feb 12, 7:27PM EST
ProfileGet Profile for:
Allergan plc
Clonshaugh Business and Technology Park
Coolock
Dublin, D17 E400
Ireland - Map
Phone: 353 8 6226 17000
Website: http://www.allergan.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:21,600

Business Summary 

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, generic, branded generic, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular, and anti-infective therapeutic categories, as well as dermatology and plastic surgery. It also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physiciansÂ’ offices. In addition, Allergan plc is developing ocular implants that reduce intraocular pressure associated with glaucoma; and an intranasal neurostimulation device, as well as other dry eye products. Allergan plc has a global development and commercialization agreement with AstraZeneca Plc regarding investigational antibiotic combination ATM-AVI. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Allergan plc

Corporate Governance 
Allergan plc’s ISS Governance QuickScore as of Feb 1, 2016 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 4; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Paul M. Bisaro , 55
Exec. Chairman
3.85M0.00
Mr. Brenton L. Saunders J.D., 46
Chief Exec. Officer, Pres and Director
2.10M0.00
Ms. Maria Teresa Hilado , 51
Chief Financial Officer and Exec. VP
31.00K0.00
Mr. Robert A. Stewart , 48
Exec. VP and Pres of Generic & Global Operations
2.11M0.00
Mr. William Meury , 47
Exec. VP and Pres of Branded Pharma
796.00K1.27M
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders